Related references
Note: Only part of the references are listed.Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data
Federico Cucchiara et al.
PHARMACOLOGICAL RESEARCH (2022)
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
Sebastian Brandner et al.
NEURO-ONCOLOGY (2021)
Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?
Federico Cucchiara et al.
PHARMACOLOGICAL RESEARCH (2020)
Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
Tae Hoon Roh et al.
SCIENTIFIC REPORTS (2020)
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
Federico Cucchiara et al.
FRONTIERS IN ONCOLOGY (2020)
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
Larraitz Egana et al.
SCIENTIFIC REPORTS (2020)
Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data
Wei Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma
Andres F. Cardona et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians
Georgios Schoretsanitis et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2018)
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power
Enrico Franceschi et al.
WORLD NEUROSURGERY (2018)
Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis
Bianca Maria Scicchitano et al.
CANCER CELL INTERNATIONAL (2018)
Therapeutic Drug Monitoring of Levetiracetam in Select Populations
Dael Jarvie et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2018)
Impact of gender on the survival of patients with glioblastoma
Minjie Tian et al.
BIOSCIENCE REPORTS (2018)
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches
Jeffrey M. Politsky
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics
H. A. Gefroh-Grimes et al.
ACTA NEUROLOGICA SCANDINAVICA (2016)
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Caroline Happold et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
Giovanni Brigliadori et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Does the choice of antiepileptic drug affect survival in glioblastoma patients?
Kristin M. Knudsen-Baas et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
Salveena Schiffgens et al.
ONCOTARGET (2016)
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme
Young-Hoon Kim et al.
CANCER (2015)
Medical management of brain tumors and the sequelae of treatment
David Schiff et al.
NEURO-ONCOLOGY (2015)
Treatment of epileptic seizures in brain tumors: a critical review
R. Bauer et al.
NEUROSURGICAL REVIEW (2014)
Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)
Daria Stepanova et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2014)
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Dominik Sturm et al.
NATURE REVIEWS CANCER (2014)
The strategy for enhancing temozolomide against malignant glioma
Mitsutoshi Nakada et al.
FRONTIERS IN ONCOLOGY (2012)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide
George C. Bobustuc et al.
NEURO-ONCOLOGY (2010)
Early presentation of de novo high grade glioma with epileptic seizures: electroclinical and neuroimaging findings
Rosario Rossi et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2010)
Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group
M. Riva et al.
NEUROLOGICAL SCIENCES (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
GE Keles et al.
JOURNAL OF NEUROSURGERY (2004)
Serum concentrations of levetiracetam in epileptic patients: The influence of dose and co-medication
TW May et al.
THERAPEUTIC DRUG MONITORING (2003)
Share Paper
